TickerFacts.

Protalix BioTherapeutics, Inc. (PLX): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2017-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$25.75M
Year ended 2025-12-31
$55.79M
Trailing 12 months to 2026-06-30
-2.8%
3-year compound annual growth
-13.1%
5-year compound annual growth
$52.02M2009-12-31: -$3.19M2010-12-31: $2.26M2011-12-31: $6.86M2012-12-31: $26.73M2014-12-31: $2.89M2015-12-31: $3.63M2016-12-31: $801.0K2017-12-31: $5.85M2018-12-31: $24.94M2019-12-31: $43.80M2020-12-31: $52.02M2021-12-31: $22.00M2022-12-31: $28.05M2023-12-31: $42.51M2024-12-31: $29.08M2025-12-31: $25.75M$25.75M
2009-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$25.75M-11.4%2026-03-18, From 2025-01-01
2024-12-31$29.08M-31.6%2026-03-18, From 2024-01-01
2023-12-31$42.51M+51.6%2026-03-18, From 2023-01-01
2022-12-31$28.05M+27.5%2025-03-17, From 2022-01-01
2021-12-31$22.00M-57.7%2024-03-14, From 2021-01-01
2020-12-31$52.02M+18.8%2023-02-27, From 2020-01-01
2019-12-31$43.80M+75.6%2022-03-31, From 2019-01-01
2018-12-31$24.94M+326.5%2021-03-30, From 2018-01-01
2017-12-31$5.85Mn/c2020-03-12, From 2017-01-01
2016-12-31$801.0K-78.0%2019-03-18, From 2016-01-01
2015-12-31$3.63M+25.6%2018-03-06, From 2015-01-01
2014-12-31$2.89Mn/a2017-03-16, From 2014-01-01
No annual figure between 2012-12-31 and 2014-12-31.
2012-12-31$26.73M+289.5%2015-03-12, From 2012-01-01
2011-12-31$6.86M+203.7%2014-03-13, From 2011-01-01
2010-12-31$2.26Mn/m2013-02-28, From 2010-01-01
2009-12-31-$3.19Mn/a2012-02-27, From 2009-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Protalix BioTherapeutics, Inc. (PLX)2025-12-31$25.75M-11.4%
Champions Oncology, Inc. (CSBR)2026-04-30$28.52M-0.1%
Kymera Therapeutics, Inc. (KYMR)2025-12-31$0n/a
Compugen Ltd (CGEN)2025-12-31$63.51M+218.6%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$3.73M-72.6%
Autolus Therapeutics plc (AUTL)2025-12-31-$20.98Mn/m
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$29.36Mn/m
Scilex Holding Co (SCLX)2025-12-31$19.65M-50.7%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$12.81Mn/a

Compare PLX, CSBR, KYMR, CGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗